Plain-English translation of NCT06239116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called RM-718 that is given as a weekly injection under the skin. The study includes people with different types of obesity—some people with general obesity, some who developed obesity after brain injury or surgery, and some with Prader-Willi syndrome. Researchers want to learn if this medication is safe and whether it helps with weight management.
For some people, obesity happens because of a problem in a part of the brain called the hypothalamus, or because of a genetic condition like Prader-Willi syndrome. Current treatments don't work well for these specific types of obesity, so researchers are testing this new medication to see if it offers a better option.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the study you join, you may receive either the new medication or a placebo injection once a week for 1 to 6 months. Some participants will receive a single dose, while others will receive multiple doses over several weeks or months. All injections are given under the skin at study visits, and you'll have regular check-ins with the research team to monitor how you're doing and check for any side effects.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States